Takeda finishes construction of Russian pharmaceutical plant
MOSCOW. Sept 11 (Interfax) - Japan's Takeda Pharmaceuticals has completed its construction of an enterprise worth 75 million euro able to produce medications in Yaroslavl, the company said in a press release.
Production should start in 2014. The plant will produce solid-dosage medications and sterile solutions for the Russian market. The plant will first produce cardiomagnil, actovegin, and calcium d3 nycomed.
During the project's first stage, total production will come to 90 million ampoules and over 2 billion pills a year. Production of liquid medications at the plant includes preparation of solutions, washing of ampoules, their sterilization, filling, quality control and packaging. The production of solid-dosage medications also covers all technological stages, from balancing, mixing and granulation to tableting, coating and packaging.
"Russia is the biggest quickly emerging market for us in terms of total sales and we expect that it will make a significant contribution to Takeda's overall growth in the coming years," Takeda's president and CEO, Yasuchika Hasegawa, was quoted in the press release as saying.
Takeda now ranks seventh in terms of sales on the Russian pharmaceutical markets. According to IMS Health, Russia's pharmaceuticals market came to $14.7 billion in 2011. Annual market growth between 2012 and 2016 should come to 11%. Takeda hopes to boost its sales in Russia by 15% annually during this period.
In autumn 2011, Takeda acquired Swiss pharmaceutical company Nycomed for 9.6 billion euro. The acquisition allowed Takeda to expand its presence on emerging markets such as a Russia and Brazil, as well as enter developed European markets such as Germany and Spain.